Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab subcutaneous add-on therapy versus placebo in adult polymyositis or dermatomyositis
NL-OMON60518Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in polymyositis (PM), dermatomyositis (DM) and Autoimmune Myopathies, sponsored by AstraZeneca. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
polymyositis (PM)dermatomyositis (DM)Autoimmune Myopathies
Beyond the preview
Go deeper on NL-OMON60518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60518.